8) Primary outcome measures: Must include at least one of the following core outcome measures: alanine aminotransferase (ALT), aspartate aminotransferase (AST), total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), and NAFLD Activity Score (NAS). This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.